Federal Circuit limits IPR estoppel for ongoing reexaminations

David McCombs and Jonathan Bowser of Haynes Boone examine a recent Federal Circuit decision holding that IPR estoppel does ...
pharmaphorum

Inter partes review in generic drug litigation—Why the USPTO should exercise its discretion to deny IPR petitions in appropriate Hatch–Waxman Act disputes

The Hatch–Waxman Act, enacted nearly 30 years ago, reflects a negotiated balance between making generic drugs more readily accessible and protecting the significant investment made by brand name ...